The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NuTide: 302—A phase Ib study of the ProTide NUC-3373 in combination with standard therapies in advanced colorectal cancer.
 
Kristen Keon Ciombor
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Research to Practice; Research to Practice; Research to Practice; Research to Practice; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Nucana (Inst); Nucana (Inst); Nucana (Inst); Nucana (Inst); Onyx (Inst); Onyx (Inst); Onyx (Inst); Onyx (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst)
 
Janet Shirley Graham
Consulting or Advisory Role - Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre
Speakers' Bureau - Amgen; Amgen; Amgen; Amgen
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Nucana; Nucana; Nucana; Nucana
 
Francesca Aroldi
Travel, Accommodations, Expenses - Nucana; Nucana; Nucana; Nucana
 
Andrew L. Coveler
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Halozyme; Halozyme; Halozyme; Halozyme; Merrimack; Merrimack; Merrimack; Merrimack; Seagen; Seagen; Seagen; Seagen
Research Funding - AbGenomics International (Inst); AbGenomics International (Inst); AbGenomics International (Inst); AbGenomics International (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Novocure (Inst); Novocure (Inst); Novocure (Inst); Novocure (Inst); Onconova Therapeutics (Inst); Onconova Therapeutics (Inst); Onconova Therapeutics (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst); XBiotech (Inst); XBiotech (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Abbvie; Abbvie; Abbvie; Abbvie; Halozyme; Halozyme; Halozyme; Halozyme
 
Benjamin L. Schlechter
No Relationships to Disclose
 
Jeffrey William Clark
Consulting or Advisory Role - Emas pharma; Emas pharma; Emas pharma; Emas pharma
Research Funding - Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
 
Jill Graham
No Relationships to Disclose
 
Lisa Jane Rodgers
No Relationships to Disclose
 
Aimery De Gramont
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical
 
Josep Tabernero
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; BeiGene; BeiGene; BeiGene; BeiGene; Biocartis; Biocartis; Biocartis; Biocartis; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Genentech; Genentech; Genentech; Genentech; Genmab; Genmab; Genmab; Genmab; HalioDx; HalioDx; HalioDx; HalioDx; Halozyme; Halozyme; Halozyme; Halozyme; Imugene; Imugene; Imugene; Imugene; Inflection Biosciences; Inflection Biosciences; Inflection Biosciences; Inflection Biosciences; Ipsen; Ipsen; Ipsen; Ipsen; Kura Oncology; Kura Oncology; Kura Oncology; Kura Oncology; Lilly; Lilly; Lilly; Lilly; Menarini; Menarini; Menarini; Menarini; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merrimack; Merrimack; Merrimack; Merrimack; Merus; Merus; Merus; Merus; Molecular Partners; Molecular Partners; Molecular Partners; Molecular Partners; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Peptomyc; Peptomyc; Peptomyc; Peptomyc; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; ProteoDesign; ProteoDesign; ProteoDesign; ProteoDesign; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Roche; Roche; Roche; Roche; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Servier; Servier; Servier; Servier; Symphogen; Symphogen; Symphogen; Symphogen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; VCN Biosciences; VCN Biosciences; VCN Biosciences; VCN Biosciences
 
Jordan Berlin
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Arno Therapeutics; Arno Therapeutics; Arno Therapeutics; Arno Therapeutics; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer Health; Bayer Health; Bayer Health; Bayer Health; Celgene; Celgene; Celgene; Celgene; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Cornerstone Pharmaceuticals; Cornerstone Pharmaceuticals; Cornerstone Pharmaceuticals; Cornerstone Pharmaceuticals; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; ipsen; ipsen; ipsen; ipsen; lsk biopharma; lsk biopharma; lsk biopharma; lsk biopharma; qed therapeutics; qed therapeutics; qed therapeutics; qed therapeutics; Seagen; Seagen; Seagen; Seagen
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); boston biomedical (Inst); boston biomedical (Inst); boston biomedical (Inst); boston biomedical (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); pfizer (Inst); pfizer (Inst); pfizer (Inst); pfizer (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); PsiOxus Therapeutics (Inst); PsiOxus Therapeutics (Inst); PsiOxus Therapeutics (Inst); PsiOxus Therapeutics (Inst); Symphogen (Inst); Symphogen (Inst); Symphogen (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Abbvie; Abbvie; Abbvie; Abbvie; Bayer; Bayer; Bayer; Bayer; boston Biomedical; boston Biomedical; boston Biomedical; boston Biomedical; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Seagen; Seagen; Seagen; Seagen
Other Relationship - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
 
Sarah Patricia Blagden
Stock and Other Ownership Interests - RNA Guardian; RNA Guardian; RNA Guardian; RNA Guardian; RNA Guardian (I); RNA Guardian (I); RNA Guardian (I); RNA Guardian (I)
Speakers' Bureau - Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; OCTIMET; OCTIMET; OCTIMET; OCTIMET
Research Funding - Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Nucana (Inst); Nucana (Inst); Nucana (Inst); Nucana (Inst); octimet (Inst); octimet (Inst); octimet (Inst); octimet (Inst); Piqur (Inst); Piqur (Inst); Piqur (Inst); Piqur (Inst); Redx Pharma (Inst); Redx Pharma (Inst); Redx Pharma (Inst); Redx Pharma (Inst); Sierra Pharma (Inst); Sierra Pharma (Inst); Sierra Pharma (Inst); Sierra Pharma (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - WO 2016075455 A1 circulating LARP1; WO 2016075455 A1 circulating LARP1; WO 2016075455 A1 circulating LARP1; WO 2016075455 A1 circulating LARP1
Travel, Accommodations, Expenses - Nucana; Nucana; Nucana; Nucana; Tesaro; Tesaro; Tesaro; Tesaro
 
T.R. Jeffry Evans
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
Consulting or Advisory Role - Karus Therapeutics (Inst); Karus Therapeutics (Inst); Karus Therapeutics (Inst); Karus Therapeutics (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Basilea (Inst); Basilea (Inst); Basilea (Inst); Basilea (Inst); Beigene (Inst); Beigene (Inst); Beigene (Inst); Beigene (Inst); Bicycle Therapeutics (Inst); Bicycle Therapeutics (Inst); Bicycle Therapeutics (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Medivir (Inst); Medivir (Inst); Medivir (Inst); Medivir (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); MiNA Therapeutics (Inst); MiNA Therapeutics (Inst); MiNA Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Verastem (Inst); Verastem (Inst); Verastem (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre
Other Relationship - Genmab; Genmab; Genmab; Genmab